Browse PCK1

Summary
SymbolPCK1
Namephosphoenolpyruvate carboxykinase 1 (soluble)
Aliases PEPCK-C; PEPCK1; PEPCKC; phosphoenolpyruvate carboxykinase, cytosolic; phosphoenolpyruvate carboxylase; Phos ......
Chromosomal Location20q13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm.
Domain PF00821 Phosphoenolpyruvate carboxykinase
character(0) character(0)
Function

Catalyzes the conversion of oxaloacetate (OAA) to phosphoenolpyruvate (PEP), the rate-limiting step in the metabolic pathway that produces glucose from lactate and other precursors derived from the citric acid cycle.

> Gene Ontology
 
Biological Process GO:0001101 response to acid chemical
GO:0001666 response to hypoxia
GO:0002237 response to molecule of bacterial origin
GO:0005996 monosaccharide metabolic process
GO:0006006 glucose metabolic process
GO:0006066 alcohol metabolic process
GO:0006071 glycerol metabolic process
GO:0006090 pyruvate metabolic process
GO:0006094 gluconeogenesis
GO:0006107 oxaloacetate metabolic process
GO:0006114 glycerol biosynthetic process
GO:0006165 nucleoside diphosphate phosphorylation
GO:0006473 protein acetylation
GO:0006475 internal protein amino acid acetylation
GO:0006638 neutral lipid metabolic process
GO:0006639 acylglycerol metabolic process
GO:0006641 triglyceride metabolic process
GO:0007568 aging
GO:0009132 nucleoside diphosphate metabolic process
GO:0009267 cellular response to starvation
GO:0009268 response to pH
GO:0009743 response to carbohydrate
GO:0009746 response to hexose
GO:0009750 response to fructose
GO:0009991 response to extracellular stimulus
GO:0010447 response to acidic pH
GO:0014074 response to purine-containing compound
GO:0014823 response to activity
GO:0016051 carbohydrate biosynthetic process
GO:0019318 hexose metabolic process
GO:0019319 hexose biosynthetic process
GO:0019400 alditol metabolic process
GO:0019401 alditol biosynthetic process
GO:0019432 triglyceride biosynthetic process
GO:0019751 polyol metabolic process
GO:0031667 response to nutrient levels
GO:0031668 cellular response to extracellular stimulus
GO:0031669 cellular response to nutrient levels
GO:0032496 response to lipopolysaccharide
GO:0032526 response to retinoic acid
GO:0032868 response to insulin
GO:0032869 cellular response to insulin stimulus
GO:0033500 carbohydrate homeostasis
GO:0033762 response to glucagon
GO:0034284 response to monosaccharide
GO:0034612 response to tumor necrosis factor
GO:0034637 cellular carbohydrate biosynthetic process
GO:0036293 response to decreased oxygen levels
GO:0036294 cellular response to decreased oxygen levels
GO:0042593 glucose homeostasis
GO:0042594 response to starvation
GO:0043200 response to amino acid
GO:0043434 response to peptide hormone
GO:0043543 protein acylation
GO:0043648 dicarboxylic acid metabolic process
GO:0044262 cellular carbohydrate metabolic process
GO:0044283 small molecule biosynthetic process
GO:0044723 single-organism carbohydrate metabolic process
GO:0045017 glycerolipid biosynthetic process
GO:0046165 alcohol biosynthetic process
GO:0046173 polyol biosynthetic process
GO:0046327 glycerol biosynthetic process from pyruvate
GO:0046364 monosaccharide biosynthetic process
GO:0046460 neutral lipid biosynthetic process
GO:0046463 acylglycerol biosynthetic process
GO:0046486 glycerolipid metabolic process
GO:0046683 response to organophosphorus
GO:0046939 nucleotide phosphorylation
GO:0051365 cellular response to potassium ion starvation
GO:0051591 response to cAMP
GO:0061402 positive regulation of transcription from RNA polymerase II promoter in response to acidic pH
GO:0070482 response to oxygen levels
GO:0070555 response to interleukin-1
GO:0070741 response to interleukin-6
GO:0071214 cellular response to abiotic stimulus
GO:0071229 cellular response to acid chemical
GO:0071300 cellular response to retinoic acid
GO:0071320 cellular response to cAMP
GO:0071322 cellular response to carbohydrate stimulus
GO:0071326 cellular response to monosaccharide stimulus
GO:0071331 cellular response to hexose stimulus
GO:0071332 cellular response to fructose stimulus
GO:0071347 cellular response to interleukin-1
GO:0071356 cellular response to tumor necrosis factor
GO:0071375 cellular response to peptide hormone stimulus
GO:0071377 cellular response to glucagon stimulus
GO:0071396 cellular response to lipid
GO:0071407 cellular response to organic cyclic compound
GO:0071417 cellular response to organonitrogen compound
GO:0071453 cellular response to oxygen levels
GO:0071456 cellular response to hypoxia
GO:0071467 cellular response to pH
GO:0071468 cellular response to acidic pH
GO:0071496 cellular response to external stimulus
GO:1901615 organic hydroxy compound metabolic process
GO:1901617 organic hydroxy compound biosynthetic process
GO:1901652 response to peptide
GO:1901653 cellular response to peptide
GO:1904640 response to methionine
Molecular Function GO:0000287 magnesium ion binding
GO:0004550 nucleoside diphosphate kinase activity
GO:0004611 phosphoenolpyruvate carboxykinase activity
GO:0004613 phosphoenolpyruvate carboxykinase (GTP) activity
GO:0005525 GTP binding
GO:0016776 phosphotransferase activity, phosphate group as acceptor
GO:0016829 lyase activity
GO:0016830 carbon-carbon lyase activity
GO:0016831 carboxy-lyase activity
GO:0019001 guanyl nucleotide binding
GO:0019003 GDP binding
GO:0019205 nucleobase-containing compound kinase activity
GO:0030145 manganese ion binding
GO:0031406 carboxylic acid binding
GO:0032561 guanyl ribonucleotide binding
GO:0043168 anion binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa03320 PPAR signaling pathway
hsa04068 FoxO signaling pathway
hsa04151 PI3K-Akt signaling pathway
hsa04152 AMPK signaling pathway
hsa04910 Insulin signaling pathway
hsa04920 Adipocytokine signaling pathway
hsa04922 Glucagon signaling pathway
hsa04964 Proximal tubule bicarbonate reclamation
hsa00010 Glycolysis / Gluconeogenesis
hsa00020 Citrate cycle (TCA cycle)
hsa00620 Pyruvate metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-2161541: Abacavir metabolism
R-HSA-2161522: Abacavir transport and metabolism
R-HSA-1266738: Developmental Biology
R-HSA-70263: Gluconeogenesis
R-HSA-70326: Glucose metabolism
R-HSA-1430728: Metabolism
R-HSA-71387: Metabolism of carbohydrates
R-HSA-381340: Transcriptional regulation of white adipocyte differentiation
Summary
SymbolPCK1
Namephosphoenolpyruvate carboxykinase 1 (soluble)
Aliases PEPCK-C; PEPCK1; PEPCKC; phosphoenolpyruvate carboxykinase, cytosolic; phosphoenolpyruvate carboxylase; Phos ......
Chromosomal Location20q13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PCK1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between PCK1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26321681MelanomaPromote immunity (T cell function)Moreover, PCK1-overexpressing T cells restricted tumor growth and prolonged the survival of melanoma-bearing mice.
Summary
SymbolPCK1
Namephosphoenolpyruvate carboxykinase 1 (soluble)
Aliases PEPCK-C; PEPCK1; PEPCKC; phosphoenolpyruvate carboxykinase, cytosolic; phosphoenolpyruvate carboxylase; Phos ......
Chromosomal Location20q13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PCK1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPCK1
Namephosphoenolpyruvate carboxykinase 1 (soluble)
Aliases PEPCK-C; PEPCK1; PEPCKC; phosphoenolpyruvate carboxykinase, cytosolic; phosphoenolpyruvate carboxylase; Phos ......
Chromosomal Location20q13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PCK1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.6050.39
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3190.77
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)871.3050.169
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.5870.32
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.080.953
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.4220.345
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-1.1320.342
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.850.619
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-3.2940.0663
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.5930.696
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.7980.126
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.5970.166
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PCK1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.46.80.61
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.48.5-1.11
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.35.98.40.613
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.49.16.31
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 382715.83.712.10.224
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221318.27.710.50.63
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161412.5012.50.485
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolPCK1
Namephosphoenolpyruvate carboxykinase 1 (soluble)
Aliases PEPCK-C; PEPCK1; PEPCKC; phosphoenolpyruvate carboxykinase, cytosolic; phosphoenolpyruvate carboxylase; Phos ......
Chromosomal Location20q13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PCK1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPCK1
Namephosphoenolpyruvate carboxykinase 1 (soluble)
Aliases PEPCK-C; PEPCK1; PEPCKC; phosphoenolpyruvate carboxykinase, cytosolic; phosphoenolpyruvate carboxylase; Phos ......
Chromosomal Location20q13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PCK1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PCK1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPCK1
Namephosphoenolpyruvate carboxykinase 1 (soluble)
Aliases PEPCK-C; PEPCK1; PEPCKC; phosphoenolpyruvate carboxykinase, cytosolic; phosphoenolpyruvate carboxylase; Phos ......
Chromosomal Location20q13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PCK1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPCK1
Namephosphoenolpyruvate carboxykinase 1 (soluble)
Aliases PEPCK-C; PEPCK1; PEPCKC; phosphoenolpyruvate carboxykinase, cytosolic; phosphoenolpyruvate carboxylase; Phos ......
Chromosomal Location20q13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PCK1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPCK1
Namephosphoenolpyruvate carboxykinase 1 (soluble)
Aliases PEPCK-C; PEPCK1; PEPCKC; phosphoenolpyruvate carboxykinase, cytosolic; phosphoenolpyruvate carboxylase; Phos ......
Chromosomal Location20q13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PCK1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPCK1
Namephosphoenolpyruvate carboxykinase 1 (soluble)
Aliases PEPCK-C; PEPCK1; PEPCKC; phosphoenolpyruvate carboxykinase, cytosolic; phosphoenolpyruvate carboxylase; Phos ......
Chromosomal Location20q13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PCK1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting PCK1.
ID Name Drug Type Targets #Targets
DB01819PhosphoenolpyruvateSmall MoleculeENO3, PCK12
DB020081-(2-Fluorobenzyl)-3-Butyl-8-(N-Acetyl-4-Aminobenzyl)-XanthineSmall MoleculePCK11
DB032671-Allyl-3-Butyl-8-(N-Acetyl-4-Aminobenzyl)-XanthineSmall MoleculePCK11
DB03725Phosphomethylphosphonic Acid-Guanylate EsterSmall MoleculePCK11